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Abstract Anti-Ro/SSA antibodies are associated with
neonatal lupus (congenital heart block (CHB), neonatal
transient skin rash, hematological and hepatic abnormalities),
but do not negatively affects other gestational outcomes, and
the general outcome of these pregnancies is now good, when
followed by experienced multidisciplinary teams. The prev-
alence of CHB, defined as an atrioventricular block diagnosed
in utero, at birth, or within the neonatal period (0–27 days
after birth), in the offspring of an anti-Ro/SSA-positive
women is 1–2%, of neonatal lupus rash around 10–20%,
while laboratory abnormalities in asymptomatic babies can be
detected in up to 27% of cases. The risk of recurrence of CHB
is ten times higher. Most of the mothers are asymptomatic at
delivery and are identified only by the birth of an affected
child. Half of these asymptomatic women develop symptoms
of a rheumatic disease, most commonly arthralgias and
xerophtalmia, but few develop lupus nephritis. A standard
therapy for CHB is still matter of investigation, although
fluorinated corticosteroids have been reported to be effective
for associated cardiomyopathy. Serial echocardiograms and
obstetric sonograms, performed at least every 1–2 weeks
starting from the 16th week of gestational age, are recom-
mended in anti-Ro/SSA-positive pregnant women to detect
early fetal abnormalities that might be a target of preventive
therapy.
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Abbreviations
ANA Anti-nuclear antibodies
AV Atrioventricular
CHB Congenital heart block
ECG Electrocardiogram
NLS Neonatal Lupus Syndromes
SLE Systemic lupus erythematosus
SS Primary Sjögren’s syndrome
UCTD Undifferentiated connective tissue disease
Anti-Ro/SSA antibodies are linked to the development of
congenital heart block (CHB) in utero and to other clinical
manifestations in newborns such as skin rash, liver
abnormalities, thrombocytopenia, etc. In contrast, it is not
clear if these antibodies are linked to other adverse
pregnancy outcomes, both in systemic lupus erythematosus
(SLE) and in non-SLE women. Neonatal lupus was so
termed because the cutaneous lesions of the neonate
resemble those seen in SLE. Notably, this might be a
misleading name, because the baby does not have SLE and
usually neither does the mother.
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Anti-Ro/SSA and anti-La/SSB antibodies
Ribonucleoproteins (RNPs) are common targets of the
humoral autoimmune response. These proteins interact with
nucleic acids and RNA in particular. They are evolution-
arily conserved molecules and RNPs have putatively been
involved in the regulation of transcription and transduction,
in RNA trafficking from nucleoli to cytoplasm, ribosome
biogenesis, and in RNA rearrangement and complexing
during the cell response to stress and apoptosis. Ro/SSA
and La/SSB are two of the major immunogenic RNPs
and antibodies against them may arise in a number of
connective tissue diseases, especially Sjögren's syndrome
(SS) and SLE [1]. They can be complexed with a family of
small cytoplasmic RNAs called human cytoplasmic (hY)
RNA [2]. These are synthesized by the enzyme RNA-
polymerase III, target of autoimmune responses itself [3].
Ro60 binds YRNAs, while La can interact with other RNA-
polymerase III products, being indeed considered a crucial
factor of the regulation of this enzyme's activity [4]. It is
still controversial whether Ro52 actually binds directly
to RNA since it unlike Ro60 does not have an RNA
recognition motif. Localization of Ro and La can be nuclear
when not incorporated in the RNP complex, while is
mainly cytoplasmic once bound to their RNA ligands [5].
Ro60 is a 60-kD protein composed of two domains: one
resembles the von Willebrand Factor A, also present in
extracellular-matrix proteins and peptides that mediate cell-
adhesion. The other domain shows alpha-elical structures
arranged together to leave an inner hole and is also
responsible for nucleic acid binding [6]. Ro52 has a
52-kD molecular weight. It belongs to a protein family
involved in regulation of transcription and ubiquitination
characterized by a common conformation made of an N-
terminal RING finger, a B-box domain and a coiled-coil
domain with a leucine zipper motif [7]. La is a 48 kD
molecular weight phosphoprotein with various domains
showing N-terminal RNA recognition motifs and C-
terminal nuclear localization signals that are necessary to
carry out the La housekeeping functions of RNAs'
chaperone with a significant influence on their downstream
processing [4]. The development of autoantibodies to the
Ro/La complex recapitulates most of the common pathways
of autoimmunity whose understanding has significantly
contributed to clarify at least in part the role of the humoral
branch of the immune system in determining/favoring
autoimmune diseases and their manifestations. Their fre-
quency varies in different diseases, being higher in SS than
in SLE and much lower in other connective tissue diseases
such as systemic sclerosis, undifferentiated connective
tissue disease (UCTD) or in rheumatoid arthritis (see Table 1)
[3, 8]. Anti-Ro/SSA (both to the 52 kD and the 60 kD forms)
and anti-La/SSB are strongly associated to given HLA
genotypes [9], but genetic susceptibility is not sufficient per
se to determine their appearance. Environmental stresses
(UV-radiations, viral infection, oxidation, etc.) are crucial
contributors to autoantibody production in this setting.
During apoptotic rearrangement, intracellular components
including both Ro and La proteins may become available to
the extracellular compartment. It has been demonstrated that
Ro60 is translocated in the early phases followed by a later
translocation of the La protein to the surface blebs of
apoptotic cells. This different dynamic may suggest an
independent regulation of these two epitopes which could be
critical in mediating the additive effect of their autoantibody
counterparts in increasing the risk of tissue injury, e.g., in
apoptotic fetal cardiomyocytes in CHB. It is thus in their
involvement in nucleic acid regulation and apoptotic
processes that immunogenicity of the Ro–La/RNP complex
mainly reside. Autoantibodies recognizing multiple peptide
sequences covering almost the entire length of Ro60 have
been described and all have been shown to be highly
conformation-dependent [4]. Epitope mapping of anti-Ro52
response has identified the middle part of the coiled-coil
region as the immunodominant sequence, spanning from
aa169 to aa291 containing the leucine zipper domain [7]. A
finer specificity of the anti-Ro 52 response has been further
clarified to reside on aa200-239 (p200) and specifically
defined as anti-p200. Anti-p200 has been the focus of recent
attention regarding the risk of CHB [10]. Yet, this higher risk
for CHB has not invariably been demonstrated and deserves
further investigation [11, 12]. An interesting link between
Table 1 Prevalence of anti-Ro/SSA and anti-La/SSB antibodies in different autoimmune rheumatic diseases
Anti-Ro/SSA Anti-La/SSB Ref.
Sjögren's syndrome 60–90% 30–60% Routsias JG, et al. Clinic Rev Allerg Immunol 2007
Systemic lupus erythematosus 30–50% 10–40% Franceschini F, Cavazzana I. Autoimmunity 2005
Systemic sclerosis 12% 4% Codullo V, et al. Future Rheumatol 2006
Rheumatoid Arthritis 11% – Franceschini F, Cavazzana I. Autoimmunity 2005
Undifferentiated connective tissue disease 8–30% – Belfiore N, et al. J Bone Spine 2000
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the Ro–La/RNP-RNA complex and the immune system has
been suggested and can represent a crucial bridge between
innate and adaptive immunity in promoting autoimmune
mechanisms; Y RNAs are capable of autologous activation
of dendritic cells, mainly through the engagement of Toll-
like receptors (TLRs). Furthermore, different Y RNAs have
different TLR stimulatory capacity and this variable spec-
trum of interactions is also mirrored by distinct clinico-
pathologic expressions [2]. This mechanism could possibly
account for the perpetuation of damage mediated by anti-Ro/
SSA antibodies, and we could postulate that, in a genetically
susceptible environment, the concurrence of stress-induced
increased apoptosis, blockade of apoptotic bodies removal
and defective YRNAs clearance due to anti-Ro/SSA auto-
antibodies, can cause exposure to immune cells generating
aberrant endogenous signals.
It is not clarified whether antibodies to Ro60, Ro52, and
La are the result of an altered immune response which
develops independently or are themselves initiators of the
immune perturbation characterizing autoimmune diseases
where they can be detected. Nevertheless, they represent an
invaluable tool for diagnostic purposes, for their clinical
associations and for their prognostic meaning (e.g., man-
dating careful monitoring of patients during pregnancy).
General pregnancy outcome in women
with autoimmune diseases and anti-Ro/SSA antibodies
Most of the available data derive from retrospective
studies; some of which reported anti-Ro/SSA antibodies
as a possible causative factor for reproductive failure and
unexplained pregnancy loss in women with autoimmune
diseases [13–15]. Small or retrospective studies have
addressed this problem, but their retrospective nature is a
strong limitation: in fact even data such as the total number
of pregnancies might be incorrect in a retrospective analysis.
Hull et al. reported on three anti-Ro/SSA-positive SLE
women with a history of spontaneous abortion [13]; Barclay
et al. reported on one patient with 2 spontaneous abortions
and a stillbirth [14], and Watson et al. described a direct
correlation of anti-Ro/SSA antibodies with pregnancy loss
only in black SLE patients [15]. Julkunen did a retrospective
analysis of the fetal outcome in 55 pregnancies in 21 patients
with primary SS compared with that in 100 pregnancies in
42 patients with SLE and 94 pregnancies in 42 healthy
women. The relative risk for fetal loss in patients with
primary SS was 2.7; in SLE was 2.2; most pregnancies in
women with primary SS occurred before the onset of the
disease. Notably Julkunen observed that the risk of preg-
nancy loss in primary SS was not associated with the
presence of antibodies to Ro/SSA or La/SSB [16]. Another
large retrospective study compared the obstetric histories of
154 anti-Ro/SSA-positive women with autoimmune diseases
(78 with SLE) to that of both 142 anti-Ro/SSA-negative
women matched for disease diagnosis and a control group of
180 healthy women [17]. The authors found that the overall
rate of pregnancy loss and adverse pregnancy outcome did
not significantly differ among the three groups. Anti-Ro/
SSA-positive SLE women reported a significantly higher
rate (18.0%) of therapeutic abortions compared with anti-Ro/
SSA-negative women (5.6%, p=0.0244) and healthy controls
(4.6%, p=0.0013). Anti-Ro/SSA non-SLE-positive women
reported a significantly higher rate of recurrent pregnancy
loss in comparison to anti-Ro/SSA-negative women (23.7% vs
7.04%, p=0.0063) and healthy controls (6.4%, p=0.0004).
The authors concluded that although anti-Ro/SSA antibodies
do not adversely affect pregnancy outcome in SLE patients,
they appear to be associated with recurrent pregnancy loss in
non-SLE patients [17]. In contrast, a small prospective study
analyzing pregnancy outcome in SLE showed that fetal loss
and IUGR correlated with the absence of anti-Ro/SSA
antibodies [18].
Based on these findings, the EULAR recommendations
for the management of SLE quoted the retrospective paper
by Watson [15] suggesting that anti-Ro/SSA positivity is
associated with fetal wastage syndrome in black women
with SLE and conclude that SLE may affect the fetus in
several ways, especially if the mother has a history of lupus
nephritis, anti-phospholipid, anti-Ro/SSA and/or anti-La/
SSB antibodies, and that these conditions are associated
with an increase of the risk of miscarriage, stillbirth,
premature delivery, intrauterine growth restriction and fetal
heart block [19]. We published the largest, prospective
study on the impact of anti-Ro/SSA antibodies on preg-
nancy outcome [20]. In a large multicentric cohort study we
have prospectively followed 100 anti-Ro/SSA-positive
women (53 SLE) during their 122 pregnancies and 107
anti-Ro/SSA-negative women (58 SLE; 140 pregnancies).
Anti-Ro/SSA antibodies were tested by immunoblot and
counterimmunoelectrophoresis. Mean gestational age at
delivery (38 vs 37.9 weeks), prevalence of pregnancy loss
(9.9% vs 18.6%), preterm birth (21.3% vs 13.9%), cesarean
sections (49.2% vs 53.4%), PROM (4.9% vs 8.1%),
preeclampsia (6.6% vs 8.1%), IUGR (0 vs 2.3%), and
newborns SGA (11.5% vs 5.8%) were similar in anti-Ro/
SSA-positive and anti-Ro/SSA-negative mothers (Table 2);
findings were similar in SLE (Table 3) and non-SLE (data
not shown) women. Our results show that anti-Ro/SSA
antibodies do not affect the pregnancy outcomes except for
the risk of CHB. In fact, we did not observe any clinically
or statistically significant difference between anti-Ro/SSA-
positive and anti-Ro/SSA-negative women, even if the
frequency of pregnancy loss in anti-Ro/SSA-positive
compared with anti-Ro/SSA-negative women was slightly
lower in SLE (9.9% vs 18.6%; relative risk, 0.53), in
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agreement with the data by Le Thi Huong [18], and slightly
higher in non-SLE (6.6% vs 1.8%; relative risk, 3.7), in
agreement with the data by Mavragani [17]. Apparently,
anti-Ro/SSA antibodies seem to have an inverse effect on
pregnancy loss in SLE and non-SLE women: looking at
pregnancy outcome, anti-Ro/SSA seem to have a favorable
impact in patients with SLE which is a severe systemic
disease, conversely, they seem to have an adverse effect in
patients with milder autoimmune conditions such as UCTD
or Sjögren’s syndrome. However, no significant differences
have been found in our study, therefore this observation
should be interpreted with extreme caution. It was also
found that the fine specificity of anti-Ro/SSA antibodies
did not affect pregnancy outcome.
Considering obstetrical history, approximately half of
the previous “historical” pregnancies reported by our women
ended with spontaneous or voluntary abortions. The retro-
spective nature of this analysis does not allow an accurate
explanation of these findings. Reasons are probably multifac-
torial: the management of the current pregnancies by high-risk
pregnancy obstetrical team; the preconception planning of
these prospective pregnancies; a selection bias, for which
women with previous negative obstetrical outcomes might be
more readily referred to centers with experience in the field.
Moreover, the striking difference emerging suggests how an
analysis of data retrospectively reported by the women
concerning their previous pregnancies might be of limited
value. On the other hand, currently the general outcomes of
the pregnancies in these autoimmune “high-risk” women can
be excellent when carefully followed by dedicated high-risk
obstetrical and multidisciplinary teams.
In conclusion, we observed in a large prospective-
controlled multicenter cohort study of anti-Ro/SSA-positive
women that the presence of these antibodies is associated
with CHB but does not negatively affect other pregnancy
outcomes, both in SLE and in non-SLE women. The general
outcome of these pregnancies is now very good (especially
important to be in remission or relative quiescent at outset),
when prospectively followed by multidisciplinary teams with
ample experience in this field.
Definition and epidemiology
Neonatal lupus is a rare disease, which affects equally
males and females (actually there may be a slight skewing
Table 2 Pregnancy outcome of all anti-Ro/SSA-positive vs all anti-Ro/SSA-negative women
Ro/SSA-positive women Ro/SSA-negative women
Number Percenta Number Percenta
No. of women 100 107
No. of pregnancies 122 140
Twin pregnancies 4 2
Living newborns 116 95.1% 125 89.3%
Total spontaneous pregnancy losses 10 8.2% 17 12.1%
Pregnancy losses <10 weeks 7 5.7% 10 7.1%
Pregnancy losses >10 weeks 3 2.4% 7 5.0%
therapeutical abortions 0 0 1 0.7%
Prematurity <37 weeks 19 15.6% 16 11.4%
Prematurity <34 weeks 3 2.5% 2 1.4%
Mean gestational age at delivery; weeks (range) 38 (30–42) 38.4(33–42)
Maternal mean age at delivery; years (range) 31.2 (25–40) 29.8(20–41)
Previous pregnancies (retrospective analysis)
Total pregnancies 44 44
Pregnancy losses <10 weeks 16 36.3% 9 20.4%
Pregnancy losses >10 weeks 5 11.4% 8 18.1%
Total spontenous pregnancy lossesb 21 47.7% 17 38.6%
Therapeutical abortions 3 6.8% 5 11.4%
a Percentages are expressed on the number of pregnancies: prospective, 122 for Ro/SSA-positive and 140 for Ro/SSA-negative women; 44
retrospective pregnancies for both
b Total spontenous pregnancy losses: in anti-Ro/SSA-positive women, prospective (10/122) vs retrospective (21/44), p<0.001; in anti-Ro/SSA-
negative women, prospective (17/140) vs retrospective (17/44), p<0.001.
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for both rash and CHB toward female in the research
registry for neonatal lupus). According to Michaëlsson [21],
complete CHB has an incidence of 1:20,000 live births;
however these numbers include also CHB associated with
congenital anatomical malformations and exclude in utero
deaths (approximately 20% of fetuses with CHB), so they
are not included in statistics which generally focus on live
births. More recently Siren [22] found an incidence of CHB
in Finland of 1:17,000 live births (95% confidence interval
1:14,000-1:21,000). Confusion exists regarding congenital
versus acquired AV block; for these reasons we propose a
new definition of congenital AV block which might be
acceptable to cardiologists, rheumatologists, pediatricians
and obstetricians: “an AV block is defined as congenital if it
is diagnosed in utero, at birth or within the neonatal period
(0–27 days after birth)”[23, 24]. These blocks are often, but
not always, associated with the presence of anti-Ro/SSA
antibodies in the mother; 10–20% may be negative for anti-
Ro/SSA and other autoantibodies as demonstrated by
Brucato [25].
Pathogenesis of neonatal lupus syndromes
Clinical manifestations of neonatal lupus are associated
with the presence of anti-Ro/SSA and La/SSB antibodies.
These antibodies, in fact, cross the placenta beginning at
approximately 12 weeks of gestation and reach the fetal
tissues [26]. The antibodies may display at least three
effects: (a) theoretically they may induce a myocarditis; (b)
they can bind apoptotic cells, block presumed physiologic
clearance and divert clearance to macrophages, and (c) they
might be arrhythmogenic. The immune-mediated damage
of the cardiac conduction system ultimately ends with
fibrotic replacement.
Apoptosis and the road to scar
One of the most intriguing aspects of CHB is that it is an
injury nearly unique to some phase(s) of fetal development,
because it has only been reported once in the maternal heart
[27] despite the presence of identical antibodies in the
Table 3 Pregnancy outcome of SLE anti-Ro/SSA-positive vs SLE anti-Ro/SSA-negative women
Ro/SSA-positive women Ro/SSA-negative women
Number Percenta Number Percenta
No. of women 53 58
No. of pregnancies 61 86
Twin pregnancies 1 0
Living newborns 56 91.9% 70 81.4%
Total spontaneous pregnancy losses 6 9.9% 16 18.6%
Pregnancy losses <10 weeks 4 6.6% 10 11.6%
Pregnancy losses >10 weeks 2 3.3% 6 7.0%
Therapeutical abortions 0 0 1 1.1%
prematurity <37 weeks 13 21.3% 12 13.9%
Prematurity <34 weeks 2 3.3% 1 1.1%
Mean gestational age at delivery; weeks (range) 38 (30–41) 37.9(33–42)
Maternal mean age at delivery; years (range) 30 (23–38) 30 (20–39)
positivity for aPL 8 14.3% 12 13.9%
SLE plus secondary APS 4 7.1% 9 10.4%
Major flares 10 17.9% 16 18.6%
Previous pregnancies (retrospective analysis)
Total pregnancies 21 22
Pregnancy losses <10 weeks 7 33.3% 4 18.1%
Pregnancy losses >10 weeks 3 14.2% 5 22.7%
Total spontenous pregnancy lossesb 10 47.6% 9 40.9%
Therapeutical abortions 1 4.8% 5 22.7%
a Percentages are expressed on the number of pregnancies: prospective, 61 for Ro/SSA-positive and 86 for Ro/SSA-negative women;
retrospective, 21 for Ro/SSA-positive and 22 for Ro/SSA-negative women
b Total spontenous pregnancy losses: in anti-Ro/SSA-positive women: prospective (6/61) vs retrospective (10/21): p<0.001; in anti-Ro/SSA-
negative women, prospective (16/86) vs retrospective (9/22), 0.05<p<0.10=NS
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maternal circulation. One of the biological stumbling blocks
has been the intracellular localization of the putative antigen
targets. It is logical to hypothesize that the target is a cardiac
surface protein containing a cross-reactive epitope recognized
by anti-Ro/La antibodies. Alternatively, the candidate antigen
might be located intracellularly and translocated to the
surface during development of the fetal heart. The genetics
of a particular fetus might be a second reasonable component.
The fact that identical twins are more often discordant than
concordant for disease suggests that an environmental factor
present in utero might be a third component. In aggregate, the
environmental factor would be expected to amplify the extent
of injury in susceptible fetuses exposed to antibodies
generated in susceptible mothers. In consideration of surface
binding, one hypothesis is that apoptosis might result in
translocation of intracellular antigens to the external leaflet of
the membrane. Applicability of apoptosis to the pathogenesis
of CHB is supported by several observations. It is a selective
process of physiologic cell deletion in embryogenesis and
normal tissue turnover plays an important role in shaping
morphologic and functional maturity. In the normal adult
myocardium, apoptosis has been observed only rarely [28]. In
contrast, apoptosis does occur during the development of the
heart [29]. Buyon's group has found that human fetal
cardiocytes are readily induced to undergo apoptosis, which
results in surface expression of components of the Ro/La
complex [30]. Furthermore, cocultured macrophages that
phagocytose apoptotic cardiocytes bound by antibodies
(opsonized) exhibit an activated phenotype compared with
macrophages that phagocytose unbound apoptotic cardio-
cytes (nonopsonized) [31]. Events subsequent to this
inflammatory cascade result in a major alteration of the
fibroblast phenotype [32], which ultimately leads to fibrosis
of the conducting system, the signature histopathologic
finding in CHB observed in all reported autopsies. For
example, the spectrum of CHB in the clinically affected fetus
includes AV nodal replacement by fibrosis or fatty tissue
[33], fibrous structures containing microscopic crystalline
structures in the conduction system [34] and altered
contractility of the working myocardium secondary to
endocardial fibroelastosis [35]. In addition, we evaluated
the role of cardiocytes in the physiologic removal of
apoptotic cells and the subsequent effect of surface binding
by anti-Ro/La antibodies [36]. Regardless of the method
used to induce apoptosis, translocation of Ro/La antigens to
the fetal cardiocyte plasma membrane was seen. When
healthy cardiocytes were cocultured with healthy cardiocytes
rendered apoptotic, a previously undescribed clearance
mechanism was revealed: proliferating cardiocytes phagocy-
tosed neighboring apoptotic cardiocytes [36]. Phagocytic
uptake was inhibited significantly after preincubation of
apoptotic cardiocytes with chicken and murine anti-Ro/La,
with IgG from an anti-Ro/La-positive mother of a CHB-
child, but not with anti-HLA class I antibody. These results
suggest that resident cardiocytes participate in physiologic
clearance of apoptotic cardiocytes, but that clearance is
inhibited by opsonization via maternal autoantibodies, result-
ing in accumulation of apoptotic cells promoting inflamma-
tion and subsequent scarring.
Genetic considerations
Candidate genes studied have been chosen based on the
proposed pathologic cascade of inflammation leading to
fibrosis. The human gene encoding trasforming growth
factor beta (TGF-β) is on chromosome 19q13 and is highly
polymorphic. Awad [37] identified five polymorphisms:
two in the promoter region at positions _800 and_509, one
at position þ72 in a nontranslated region and two in the
signal sequence at positions þ869 and þ915. The poly-
morphisms at positions þ869 and þ915, which change
codon 10 (T/C, leucine/proline) and codon 25 (G/C, arginine/
proline), are associated with interindividual variation in the
levels of TGF-β production. Several animal and human
studies have found that high TGF-β producers develop
significantly more lung fibrosis in response to a number of
inflammatory triggers, such as radiation [38], chemotherapy
[39] and lung transplantation [40]. In codon 25, the Pro25
allele is associated with lower TGF-β synthesis in vitro and
in vivo, whereas the Arg25 allele is associated with allograft
fibrosis in transbronchial biopsies when compared with
controls and with nonallograft fibrosis [41]. With regard to
codon 10, it has been reported that lung allograft recipients
with the Leu10 allele produced the highest amounts of TGF-
β [37], and chronic rejection after lung transplant is linked
with high levels of TGF-β [41]. High levels of TGF-β were
thus hypothesized to permit the development of CHB caused
by enhancement of extracellular matrix and increased
fibrosis. To evaluate this hypothesis, codons 10 and 25 of
the TGF-β gene were evaluated in 88 children (40 CHB, 17
rash, 31 unaffected siblings) and 74 mothers from the
research registry for neonatal lupus [42]. The TGF-β
polymorphism Leu10 (associated with increased fibrosis)
was significantly higher in CHB-children (genotypic frequen-
cy 60%, allelic frequency 78%) than unaffected offspring
(genotypic frequency 29%, P=.016; allelic frequency 56%,
P=.011) and controls, whereas there were no significant
differences between controls and other NLS groups. For the
TGF-β polymorphism Arg25 there were no significant
differences between NLS groups and controls [42].
The TGF-β polymorphism was evaluated in two
families, one with dizygotic twins and one with trizygotic
triplets discordant for disease expression [43]. Each family
only had one child affected with third-degree CHB,
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although another of the triplets had alternating first- and
second-degree block. In the twin family, the CHB twin was
heterozygous for the TGF-β polymorphism, whereas the
unaffected twin did not carry the profibrotic allele. Each of
the triplets was also heterozygous for TGF-β. In the two
children with third-degree CHB, TGF-β secretion was
increased in both spontaneous and mitogen-stimulated
peripheral blood mononucleocytes compared with their
siblings. These observations support a fetal contribution to
the development of neonatal lupus as well as the likelihood
that events in utero strongly contribute to the susceptibility
of a particular fetus. To help minimize these contributions,
several families in the research registry for neonatal lupus
have conceived twins via in vitro fertilization in pregnan-
cies carried by anti-Ro/La-negative surrogate mothers.
The neonatal lupus rash resembles that of subacute
cutaneous SLE (SCLE) and often is photosensitive. In
individuals with SCLE lesions having the haplotype –308A
tumor necrosis factor alpha (TNF-α)/DRB1*03, there is
evidence that the release of TNF-α by UV light-exposed
keratinocytes contributes to these lesions [44]. TNF-α is
encoded by a highly polymorphic gene and a substitution of
G/A at position –308 (TNF2) in the promoter region has
been associated with increased production of this cytokine
[45]. The –308G (TNF1) common (wild-type) allele has a
frequency of approximately 80% in whites and 92% in
African Americans [45]. The link between photosensitivity,
anti-Ro/SSA antibodies and TNF-α promoter polymor-
phisms extends to HLA class II molecules, because the
presence of DRB1*03 is common in individuals who
synthesize anti-Ro/La antibodies. Additionally, in whites,
there is a strong linkage disequilibrium between the –308A
allele and HLA-DRB1*03 [46]. DNA from the cohort
described above [42] was genotyped for the TNF-α –308
promoter region and HLA-DRB1. In children with NLS
rash, there was a significantly higher –308A carrier
frequency compared with healthy controls (64% versus
23%; P=.002) [47]. In addition, the DRB1 distribution for
DRB1*03 was significantly higher in children with rash
compared with controls (64% versus 17%; P=.014) and,
interestingly, the carrier frequency of DRB1*03 was also
significantly higher than controls for children with CHB
(54%) and for mothers (73%) but not unaffected children
(39%). The carrier frequency was higher in children with
rash compared with children without rash, although the
difference did not reach statistical significance. The
prevalence of the –308A allele paralleled the prevalence
of DRB1*03 in children with rash. For children with rash,
the association between the –308A allele and DRB1*03
occurred in every case but one (7%; P=.012 versus
control). However, in children who were unaffected and
in children with CHB, the presence of –308A in the
absence of DRB1*03 was 25% and 38%, respectively,
which did not differ significantly from controls [47].
Arrhythmogenesis and electrophysiological effects
Several publications have shown arrhythmogenic effects of
anti-Ro/SSA antibodies in experimental models that used
animal or human myocardial tissues [48–51]. In particular,
an interference of anti-Ro/SSA IgG with L-type calcium
channel has been suggested by some experimental models
[50, 52]. Furthermore, animal models have shown that
active immunization with the Ro antigen or passive
infusion of anti-Ro/SSA IgG into pregnant animals gener-
ated varying degrees of AV conduction abnormalities,
including complete AV block, in the pups [50, 51], however
the penetrance was extremely low paralleling human
disease frequencies. Another study showed that 20% of
pups born to rats immunized with the p200 peptide
developed first-degree AV block [53]. The same authors
showed that anti-Ro/SSA antibodies disturb calcium homeo-
stasis of cultured human fetal cardiocytes; in particular they
observed that p200-specific autoantibodies cloned from
patients bound cultured cardiomyocytes and severely affected
Ca2+ oscillations, leading to accumulating levels and over-
load of intracellular Ca2+ levels with subsequent loss of
contractility and ultimately apoptosis [53].
Clinical features
Cardiac manifestations
Third-degree AV block is the most severe manifestation of
neonatal lupus, since it is irreversible and carries a high
morbidity and mortality rate. The presence of signs or
symptoms is mainly related to the ventricular rate, which
usually ranges between 30 and 100 beats/minute [54, 55],
but may be also related to the cardiac contractility and to
the ratio between atrial and ventricular contractions; heart
rate usually declines during the pregnancy [56]; the lower
the rate, the higher the possibility of fetal hydrops and
neonatal cardiac failure and fetal or neonatal death
correlates with a ventricular rate in utero less than or equal
to 55 bpm [54–57].
CHB (either first, second, or third) is most frequently
detected in utero by prenatal ultrasound, between 18 and
24 weeks of gestational age. This “window” coincides with
the timing of placental transfer (that becomes effective at
about 12 weeks) and the timing of the development of the
human fetal conduction system which is formed by
12 weeks (thus explaining the absence of associated
structural abnormalities) but presumably undergoes further
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remodeling (perhaps explaining the later development of
block at 20 weeks or so). In the majority of cases complete
block requires a pacemaker implantation, frequently but not
necessarily in the neonatal period. In utero death is usually
related to intractable heart failure.
A subset of patients with CHB may develop dilated
cardiomyopathy, even if the risk seems low, approximately
6% of CHB infants [58–60]. Myocardial biopsy revealed
hypertrophy, interstitial fibrosis in most patients and
myocyte degeneration in few. The majority of affected
children dies from congestive heart failure or requires
cardiac transplantation, while a recovery was reported in
few cases [59].
CHB may be associated with endocardial fibroelastosis
and it has been reported that isolated endocardial fibroelas-
tosis may be independently related to maternal anti-Ro/SSA
and anti-La/SSB antibodies [61].
Spectrum and progression of conduction abnormalities
in infants born to mothers with anti-Ro/La antibodies
To ascertain the spectrum of arrhythmias associated with
maternal anti-Ro/La antibodies, records of all children
enrolled in the Research Registry for Neonatal Lupus were
reviewed [62]. Of 187 children with CHB whose mothers
have anti-Ro/La antibodies, nine had a prolonged PR
interval on electrocardiogram (ECG) at birth, four of whom
progressed to more advanced AV block. A child whose
younger sibling had third block was diagnosed with first
block at age 10 year at the time of surgery for a broken
wrist. Two children diagnosed in utero with second block
were treated with dexamethasone and reverted to normal
sinus rhythm by birth, but ultimately progressed to third
block. Four children had second block at birth: of these,
two progressed to third block. These data have important
research and clinical implications.
Perhaps many fetuses sustain mild inflammation, but
resolution is variable, as suggested by the presence of
incomplete AV block in some cases and progression to
complete block in others. Importantly, since subsequent
progression of less-advanced degrees of block can occur, an
ECG (to identify clinically silent first-degree block) should
be performed on all infants born to mothers with anti-Ro/La
antibodies.
Other electrocardiographic manifestations
Sinus bradycardia may be a rare and seemingly reversible
part of the spectrum of anti-Ro/SSA associated cardiac
disease [63]. QT prolongation has been reported both in
infants from mothers with anti-Ro/SSA antibodies [64] and
in adults positive for anti-Ro/SSA antibodies [65], but these
data have not been confirmed by many others [66, 67].
Thus, QT prolongation as a consequence of autoantibody
injury remains unproven.
Two useful prospective studies have been recently
published by Italian groups. In the first study [68], electro-
cardiograms prospectively obtained from 51 infants born of
anti-Ro/SSA-positive mothers were compared with those
obtained from 50 control infants born of mothers with anti-
extractable nuclear antigen-negative connective tissue dis-
ease. One anti-Ro/SSA-exposed infant developed complete
CHB. No infant showed sinus bradycardia. First-degree AV
block at birth was observed in five study group and no
control group infants, P=0.023. First-degree AV blocks
spontaneously reverted during the first year of life. Mean
corrected QT value of infants born from anti-Ro/SSA-
positive mothers was slightly prolonged but did not reach
statistical significance, as compared with the control group
(0.404 vs 0.395 s; P=0.060). In the second study, 60 anti-
Ro/SSA-positive and 36 anti-Ro/SSA-negative autoimmune
mothers were prospectively followed; ECG and/or ECG-
Holter were performed on the offspring at first, third, sixth,
and 12th month. One of 61 fetuses of anti-Ro/SSA-positive
mothers developed third-degree block, one developed
second-degree AV block (30th week). Corrected QT
interval ≥440 ms was observed in 13% of cases and in
20% of controls at the first ECG. ECG-Holter showed QTc
prolongation ≥440 ms in 59% infants of anti-Ro/SSA-
positive mothers and in 60% of controls, and QTc ≥470 ms
in four infants of anti-Ro/SSA-positive group and in two
controls. One baby in the anti-Ro/SSA-positive and two in
the anti-Ro/SSA-negative group required beta-blockers.
Genetic causes of QTc prolongation were excluded. This
prospective study showed that ECG abnormalities (first-
degree block and QTc prolongation) are frequent in infants
of mothers with autoimmune diseases particularly if ECG-
Holter is done, independently of maternal autoantibody
profile [69].
Skin rash
A skin rash can be present at birth, but more frequently, it
appears between the second and third months of life [70,
71]. Unlike CHB, it is transient since it disappears with the
clearance of maternal autoantibodies from the baby's
circulation, usually without any residua. The rash is
erythematous and scaly, similar to SCLE. It is frequently
annular in shape and most commonly located in sun-
exposed area with a characteristic predilection for the
periorbital area. Ultraviolet exposure may be an initiating
factor and can exacerbate an existing rash. Histologically,
the lesions are similar to subacute cutaneous lupus, with
hyperkeratosis, epidermal atrophy, basal degeneration,
interstitial edema and a perivascular mononuclear infiltrate.
Immunoglobulin and complement deposition have been
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demonstrated by direct immunofluorescence at the dermo-
epidermal junction. Since these lesions are self-limiting,
usually no treatment is required.
Laboratory abnormalities
Hematologic abnormalities are not common but have been
described, usually consisting of thrombocytopenia [72],
and neutropenia [73]. Hepatic involvement has also been
described [74, 75] which can vary from an asymptomatic
increase in serum transaminases to severe cholestasis. This
has been noted to be present at birth in some cases and
in others has not been clinically evident until several
weeks after birth. Cimaz observed hematologic abnor-
malities in 27% of the babies from anti-Ro/SSA-positive
mothers and elevation of liver enzymes in 26% [76].
Similar to the cutaneous manifestations but in contrast to
CHB, these manifestations are transient and usually do
not require medical intervention. On the other hand, Motta
in a prospective study observed a lower frequency of
hematologic abnormalities and no cases of hepatobiliary
disease [68].
Central nervous system involvement
Learning disabilities [77] and hydrocephalus [78] have been
associated with in utero exposure to maternal anti-Ro/SSA
antibodies, but these findings await confirmation.
Prognosis
Children
Complete CHB is a severe disease. Mortality, usually in
utero or in the first three months of life, can reach 30%
even after intensive and supportive care. Prophylactic
pacemaker treatment might be considered even in asymp-
tomatic patients because of high incidence of unpredictable
Stokes–Adams attacks and significant morbidity and
mortality. After birth and pacemaker implantation, children
can live an almost normal life. The possibility for these
children to develop SLE or another connective tissue
disease in later life is very uncommon [79, 80]. The risk
is apparently not higher than in asymptomatic children of
mothers with autoimmune diseases [80, 81]. Data from the
Research Registry for Neonatal Lupus [80] supported no
increased risk of SLE, but concern was raised regarding the
development of autoimmune disease (systemic or organ-
specific) in early childhood. Specifically, six children (all
with neonatal lupus) with definite rheumatic/autoimmune
diseases were identified: two with juvenile rheumatoid
arthritis, one with Hashimoto thyroiditis, one with psoriasis
and iritis, one with diabetes mellitus and psoriasis, and one
with congenital hypothyroidism and nephrotic syndrome.
Mothers
Follow-up studies have shown that the long-term prognosis
of mothers of babies with NLS is reasonably good, since
only approximately half eventually develop a connective
tissue disease, which in most cases is mild and non life-
threatening [82–85]. Most recently, mothers enrolled in the
Research Registry for Neonatal Lupus were analysed. Of
the 321 mothers enrolled, 229 had at least 6 months of
follow-up. Twenty-six of the 51 mothers who were
asymptomatic at the NL-child's birth progressed: 12
developed pauci-undifferentiated autoimmune syndrome
(UAS), two poly-UAS, seven SS, four SLE, and one SLE/
SS. The median time to develop any symptom was
3.15 years. Sixteen of the 37 mothers classified as pauci-
UAS at the NL-child's birth progressed: five developed
poly-UAS, six SS, four SLE, and one SLE/SS. Of the
pauci-UAS mothers enrolled within 1 year, the median time
to progression was 6.7 years. Four mothers developed lupus
nephritis (two asymptomatic, two pauci-UAS). The probabil-
ity of an asymptomatic mother developing SLE by 10 years
was 18.6%, and developing probable/definite SS was 27.9%.
NL-manifestations did not predict disease progression in an
asymptomatic mother. Mothers with anti-Ro/SSA and anti-
La/SSBwere nearly twice as likely to develop an autoimmune
disease as mothers with anti-Ro/SSA only [86].
Risk of delivering a child with complete CHB
Since women with anti-Ro/SSA antibodies are relatively
frequent but CHB is very rare, we are faced with the
following situation: frequent counseling of a rare disease. In
a prospective study, we found that the prevalence of
complete CHB in newborns of 100 women already known
to be anti-Ro/SSA positive and with known connective
tissue disease was 2% (95% confidence interval 0.2–7%)
[27]. However, we only studied mothers who had been
found to be anti-Ro/SSA positive by counterimmunoelec-
trophoresis, a method with high specificity and rather low
sensitivity, to exclude women with low or dubious titers of
anti-Ro/SSA. Our results therefore cannot be extrapolated
to women with low-positive titers of anti-Ro/SSA anti-
bodies by ELISA, for which the risk, if any, should be even
lower. Indeed most women with CHB-children do have
very high titers of anti-Ro/SSA antibodies which still
do not predict the development of CHB but rather is a
characteristic of this autoimmune response. Healthy babies
are also born of mothers with very high titers [67]. The low
risk of complete CHB has now been confirmed by other
groups: Gladman reported no cases of complete CHB in
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100 live births in 96 anti-Ro/SSA-positive women [87];
Cimaz observed two cases in 128 anti-Ro/SSA-exposed
infants (1.6%) [76], Costedoat-Chalumeau of one case out
of 99 infants (1%) [66], Gerosa reported a risk of one out of
60 (1.7%) [69], Motta of 1/51 (2%) [68], Friedman of two
out of 74 (2.7%) [67] previous pregnancies without affected
children, Rein of 0 out of 70 [88]. This risk might be further
refined taking into account other factors: anti-La/SSB
antibodies and hypothyroidism. The presence of anti-La/
SSB antibodies increases the risk of CHB to 3.1% from a
theoretical risk of 2%, while the risk decreases to 0.9% if
the mother is anti-La/SSB-negative [89]. One study
reported that mothers with hypothyroidism seem to have a
9-fold increased risk over women with normal thyroid
function of having a child with CHB (odds ratio 8.63) [90].
Askenase evaluated 54 mothers of children with CHB and
identified 14 (25.9%) whose sera contained antibodies to
thyroperoxidase and 20 (37%) to thyroglobulin (TG) [91].
Both antibody frequencies were higher than in the general
population. Anti-TG antibodies were significantly greater
than reported for a cohort of SS patients. Five of these
CHB-mothers were hypothyroid which was not increased
compared to that reported in SS. In the search for other
factors responsible for NL, anti-TG antibodies, while not
present in 100% of these sera, might be another contrib-
uting factor, the pathologic mechanism of which is not
evident.
Risk of recurrence
The mothers have higher probabilities of delivering a
second affected child. Few prospective studies exist on this
issue; however, the percentage value seems to be comprised
between 15% and 20% [92, 93].
Obstetric management of pregnancy at risk
of developing CCHB
Awoman is at risk of delivering a baby affected by CHB if
she is definitely anti-Ro/SSA positive. There are some
suggestions that anti-52-kd Ro/SSA, anti-La/SSB and anti-
p200 antibodies are more strongly associated with CHB
than anti-60-kd Ro/SSA alone, at least as tested by
immunoblot [12, 82, 94], but the data are inconclusive.
Furthermore there are issues of reproducibility, sensitivity
and specificity of the different tests (commercial kits,
research specific to different laboratories). For practical
purposes at present the key is a reliable positivity for anti-
Ro/SSA antibodies, regardless of the methods employed. If
the positivity is uncertain or the titer is very low, we advise
to confirm the positivity with standardmethods or in reference
laboratories.
Serial echocardiograms and obstetric sonograms per-
formed at least every 1–2 weeks beginning at 16 weeks of
gestation are recommended in this setting. The goal is to
detect early fetal abnormalities that might precede more
advanced blocks and thus provide a target of preventive
therapy [95]. Unfortunately, we have observed both in the
USA and in Italy, third-degree block and extensive
myocardial injury within 7 days of a normal rhythm and
PR interval [67]. Systematic prophylactic therapy with
dexamethasone or betamethasone is not recommended,
because of the low risk of CHB and the potential side
effects of this therapy. Other steroids are not useful since
they do not cross the placenta in an active form. Shinohara
[96] has reported that prenatal maintenance therapy with
prednisolone initiated before 16 weeks' gestation might
reduce the risk of developing CHB, but this paper is heavily
biased by the restrospective setting. In fact, it is now
recognized that the majority of women bearing children
with CHB do not have recognized SLE and are often
asymptomatic at the time of delivery: these women would
not have been identified had the fetal abnormality not
occurred (retrospective diagnosis).
Assessment of first-degree AV Block in utero
Several methods have been developed with the aim to
detect in utero early fetal abnormalities, particularly first-
degree AV block, which might herald CHB. The American
group have evaluated the mechanical PR interval. By using
the gated-pulsed Doppler technique, time intervals from the
onset of the mitral Awave (atrial systole) to the onset of the
aortic pulsed Doppler tracing (ventricular systole) within
the same left ventricular cardiac cycle may be measured.
Recently, 95 pregnant women with anti-Ro/SSA antibodies
completed an evaluable course in 98 pregnancies [67]. The
protocol included fetal echocardiograms performed weekly
from 16 to 26 weeks' gestation. PR intervals >150 ms were
considered prolonged, consistent with first-degree block.
Ninety-two fetuses had normal PR intervals. Neonatal lupus
developed in ten cases; four were neonatal lupus rash only.
Three fetuses had third-degree block; none had a preceding
abnormal PR interval, although in two fetuses >1 week
elapsed between echocardiographic evaluations. Tricuspid
regurgitation preceded third-degree block in one fetus and
an atrial echodensity preceded block in a second. Two
fetuses had PR intervals >150 ms. Both were detected at or
before 22 weeks, and each reversed within 1 week with
4 mg dexamethasone. No first-degree block developed after
a normal ECG at birth. Heart block occurred in three of 16
pregnancies (19%) in mothers with a previous child with
CHB and in 3 of 74 pregnancies (4%) in mothers without a
previous child with CHB or rash (P=0.067). The authors
concluded that prolongation of the PR interval was
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uncommon and did not precede more advanced block and
that advanced block and cardiomyopathy can occur within
1 week of a normal echocardiogram without initial first-
degree block. Echodensities and moderate/severe tricuspid
regurgitation merit attention as early signs of injury.
The Swedish group reported on weekly echocardiograms
performed on 24 women with anti-Ro/SSA 52-kd anti-
bodies, between 18 and 24 weeks of gestation, with two
Doppler echocardiographic methods designed to estimate
the time delay between hemodynamic events caused by atrial
and ventricular depolarizations. Fetal AV time intervals were
longer and heart rates were slightly lower compared to fetuses
not exposed to anti-Ro/SSA antibodies. Eight fetuses had
signs of first-degree block. It is of note that the cutoffs for
first-degree block were lower than those reported by Friedman
[67]. One of these fetuses (whose PR interval was abnormal
in the Swedish study but would not have been considered
abnormal in the US study) had progression to complete
block and another showed recovery from second-degree
block to first-degree block with betamethasone treatment.
In the remaining six fetuses, spontaneous normalization
occurred before or shortly after birth [97].
Recently an Israelian group proposed the tissue velocity-
based fetal kinetocardiogram (FKCG) to detect first-degree
AVB in fetuses at risk [88]. FKCG was performed in 70
fetuses of 56 anti-Ro/SSA-positive mothers. Fetuses were
monitored with weekly FKCG from 13 to 24 weeks
gestation and compared to 109 normal fetuses. FKCG was
obtained readily in all fetuses; six showed first-degree block
(AV conduction time >2 z scores above normal mean) at 21
to 34 gestational weeks. Immediate maternal treatment with
dexamethasone resulted in normalization of AV conduction
in all affected fetuses within 3 to 14 days. The ECG PR
interval immediately after birth was normal in all affected
newborns. No child developed complete CHB or cardio-
myopathy in the subsequent 1- to 6-year (median, 4 years)
follow-up. What is unknown from these three studies is the
natural history of so called first-degree block. There are
no data on spontaneous reversibility and progression to
advanced block has not been reproducibly documented
to date. This is critical and investigators are encouraged to
share echocardiographic tapes to validate the reliability of
this candidate biomarker.
Treatment
In utero therapy
There is no known effective therapy for CHB. Prenatal
interventions consist of drugs given to the mothers, the
purposes of which are to diminish the maternal autoimmune
response and/or the fetal cardiac inflammatory injury and in
some cases to increase the fetal heart rate. Corticosteroids
have been used, particularly dexamethasone and bethame-
tasone, since they are not metabolized by the placenta and
are thus available to the fetus in an active form. Steroid
therapy has been reported as effective in the resolution of
inflammatory signs (pleural effusions, ascites, and hydrops
fetalis) in a few case reports [98, 99]. However, treatment is
probably unable to revert third-degree heart block once
established (presumably, fibrosis of conducting system).
Different case series gave conflicting results. Fluorinated
steroids seemed at least partially effective in improving
overall prognosis in American [100, 101], Swedish [97]
and Israelian [88] experiences; in these studies they have
been associated with improvement in AV conduction in
first- and second-degree AV blocks [88, 97, 98], or with
disappearance of fetal effusions and improvement in
survival [98, 100, 101]. In other series, these drugs have
not been reported to have favorable effects [57, 102].
Maternal risks of fluorinated steroids are similar to any
glucocorticoid and include infection, osteoporosis, osteo-
necrosis and diabetes. Specific fetal risks include intrauter-
ine growth restriction, oligohydramnios and possibly
adrenal suppression. Besides possible maternal side effects
similar to any glucocorticoid therapy, specific fetal risks
exist (oligohydramnios). Only a randomized controlled trial
will define the role of fluorinated steroids in the treatment
of CHB. However, this may not be feasible given the rarity
of disease, the difficulty in matching the severity of cases
and resistance on the part of the mothers to agree to
randomization [100]. We presently suggest the following
schema. If the block is incomplete (e.g., second degree),
bethametasone or dexamethasone 4–8 mg daily to the
mother is started, with a note of caution: to differentiate
incomplete from complete AV block may be difficult
in utero and usually requires expertise by a pediatric
cardiologist. If the block is recent (the more common
clinical situation), bethamethasone or dexamethasone is
recommended as well; the dose is tapered and the drug is
discontinued if no change occurs after several weeks. If the
block is associated with signs of myocarditis, heart failure
or hydropic changes, betamethasone/dexamethasone is
recommended. If the block is complete and present for
more than 2–4 weeks, with no effusions and no signs of
hydrops, only serial echograms should be performed, with
no therapy. In Italy, we have recently treated with IVIG two
mothers whose fetus had complete CHB and clear evidence
of myocarditis: the myocarditis quickly resolved, but the
complete AV block persisted. A possible therapeutic window
for IVIG might be in the early treatment of complete or
incomplete AV block, or even in its prevention for high-risk
cases which is currently under study [103, 104].
On the cardiological side, salbutamol, a selective beta 2
adrenergic agonist, also named albuterol, may be useful to
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increase the fetal heart rate, to improve ventricular function
and fetal hydrops. Maternal continuous ritodrine infusion
or terbutaline may be attempted [105]. Beta 2 adrenergic
agonists may be useful particularly as a bridge to reach a
more advanced gestational age [106]. Salbutamol is the
preferred sympathomimetic agent since it can be given
orally to the mother, at a dosage of 2 mg six to ten times
daily, according to maternal compliance.
The in utero environment is preferred as long as possible
because of the low resistance circulatory pathways, thereby
affording minimal work to maintain cardiac output, as well
as the immaturity of the lungs and other organs. However,
this approach must be balanced against the heightened
transfer of maternal antibodies as the pregnancy progresses,
although the window of cardiac vulnerability may have
passed.
The problem of neuropsychological development
Evidence has accumulated on the potential harm of
repeated courses of steroids for the mother and the fetus.
Animal models suggest that repeated antenatal steroid
doses can interfere with the growth and development of
the immature brain and human observations suggest that
antenatal and postnatal dexamethasone may negatively
affect the child’s neuropsychological development [107–
109]. The possible negative effects seem more linked to
dexamethasone than betamethasone and it has been
suggested that betamethasone should be preferred when
available [110, 111]. Moreover, separate meta-analysis of
the data in the Cochrane review show that only betametha-
sone and not dexamethasone significantly reduces neonatal
mortality [112]. For these reasons, we are now moving in
Europe to use bethametasone instead of dexamethasone in
the context of CHB.
The presence of maternal anti-Ro/SSA antibodies per se
may be associated with learning disabilities in the offspring
[77]. In light of these findings, CHB babies who are both
treated in utero with high-dose dexamethasone and exposed
to maternal anti-Ro/SSA antibodies could be at risk for
neuro-developmental defects. We have therefore tested our
Italian CHB patients for neuropsychological development,
IQ and learning disabilities: 16 children were enrolled in
this study and all had normal IQ [113]. Although it is quite
possible that repeated course of dexamethasone may be
detrimental to the newborn's neurodevelopment, a child's
final intellectual maturation remains an extremely complex
process, involving the interplay of many biological, social,
and cultural factors. We observed no negative effects on the
neurodevelopment of our patients, many of them exposed
to very high dosages of dexamethasone (much higher than
those used to enhance fetal lung maturity) and to maternal
anti-Ro/SSA antibodies. CHB is a rare disease, but these
reassuring findings might be clinically relevant also for the
large number of newborns treated with repeated courses of
antenatal fluorinated steroids to induce fetal lung maturity.
Postnatal treatment
Postnatal treatment of CHB is based on pacemaker
implantation. Frequently a pacemaker is implanted in the
neonatal period. Due to the very low weight of these
subjects (often <2.5 kg) the pacemaker is implanted by
thoracotomic or sternotomic route, with an electrode on the
epicardial surface which is connected to an impulse
generator placed in an abdominal subfascial pouch. In the
presence of extreme bradycardia, isoproterenol (0.1–
0.3 μg/kg per minute) needs to be administered as well.
Pacing should be considered based on the clinical condition
and not considered mandatory in any infant. Non-cardiac
manifestations such as skin rash or hematology abnormal-
ities do not require any treatment, since they are reversible
and spontaneously disappear, usually during the second
semester of life.
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